CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Lutfi H AlfarsiRokaya El AnsariMadeleine L CrazeMichael S TossBrendah MasisiIan O EllisEmad A RakhaAndrew R GreenPublished in: Breast cancer research and treatment (2019)
CDC20 is a candidate biomarker for a subgroup of ER+ breast cancer characterised by poor clinical outcome. This study shows that the CDC20 could act as potential predictive biomarker of poor response to endocrine therapy in ER+ breast cancer.